Clinical evaluation of moxalactam therapy

Abstract

Moxalactam was evaluated clinically in 53 infected patients with significant underlying diseases. Forty-three patients (81%) responded favorably to moxalactam therapy, including 14 with infections caused by Pseudomonas aeurginosa. Mild side effects (skin rash, diarrhea, and hepatic transaminase elevation) occurred in 6 patients. Two patients developed fungemia and one developed mild elevation of serum creatinine which was attributed to moxalactam which resolved after discontinuation of therapy. Seven patients with pretreatment renal dysfunction demonstrated improvement in serum creatinine while receiving moxalactam. Organisms from 3 infections [P. aerguinosa and 1 Serratia marcescens] developed resistance during therapy. Treatment failures were more common in patients with infections due to P. aeruginosa with a minimum inhibitory concentration > 16 mg/l and with infections due to gram-positive cocci. Thus, moxalactam is effective as therapy for serious infections caused by susceptible gram-negative bacilli.